NeogenFRA:NG2 +5.08%68 Buyback Yield % is 0.00 as of Jul. 11, 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.73 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 346 Medical Devices & Instruments companies, Neogen ranks worse than 289017.05% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Neogen's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs UFPT, ALMR, BFLY: Buyback Yield % Comparison
For the Medical Devices subindustry, Neogen's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Neogen's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a Buyback Yield % of 0.00 as of Jul. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neogen and its competitors. Over the past decade, Neogen's Buyback Yield % has ranged from 0.11 to 0.11. According to the industry distribution chart, Neogen ranks #999999 out of 346 companies in the Medical Devices & Instruments industry.
Is Neogen's Buyback Yield % too high?
Neogen's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.11. Based on the distribution chart, Neogen ranks #999999 out of 346 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Buyback Yield % compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #999999 out of 346 companies for Buyback Yield %. This places Neogen in the lower half of its industry. Historically, Neogen's own Buyback Yield % has ranged from 0.11 to 0.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Neogen and its competitors. Neogen's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.73, compared to a current price of €8.40 — trading 21.8% below its estimated fair value. The current Buyback Yield % is 0.00. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Buyback Yield % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of €8.40 is trading 21.8% below its estimated GF Value™ of €10.73.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for FRA:NG2:
Buyback Yield %: 0.00
GF Value™: €10.73 vs. price of €8.40 (21.8% below fair value)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
